SEC Comment Letter for WOLVERINE PARTNERS CORP. (CIK 0001810254) — May 1, 2020

WOLVERINE PARTNERS CORP. (CIK 0001810254)
Date: May 1, 2020 · CIK: 0001810254 · Accession: 0000000000-20-003764

View on Edgar

AI Filing Summary & Sentiment

Date

May 1, 2020

Author

Not clearly detected

Form

UPLOAD

Company

WOLVERINE PARTNERS CORP. (CIK 0001810254)

Letter

United States securities and exchange commission logo May 1, 2020 Fabian Monaco President and Director Wolverine Partners Corp. 77 King Street West, Suite 400 Toronto-Dominion Centre Toronto, ON M5K 0A1 Canada Re:Wolverine Partners Corp. Draft Offering Statement on Form 1-A Submitted April 28, 2020 CIK No. 0001810254 Dear Mr. Monaco: Our initial review of your draft offering statement indicates that it fails in numerous material respects to comply with the requirements of Regulation A and Form 1-A. More specifically, your offering statement does not include audited financial statements for the fiscal year ended December 31, 2019 or an auditor's report as required by paragraph (c) of Part F/S of Form 1-A. We will provide more detailed comments relating to your draft offering statement following our review of a substantive amendment that addresses these deficiencies. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Frank Borger Gilligan

Show Raw Text

United States securities and exchange commission logo
May 1, 2020
Fabian Monaco
President and Director
Wolverine Partners Corp.
77 King Street West, Suite 400
Toronto-Dominion Centre
Toronto, ON M5K 0A1 Canada
Re:Wolverine Partners Corp.
Draft Offering Statement on Form 1-A
Submitted April 28, 2020
CIK No. 0001810254
Dear Mr. Monaco:
            Our initial review of your draft offering statement indicates that it fails in numerous
material respects to comply with the requirements of Regulation A and Form 1-A.  More
specifically, your offering statement does not include audited financial statements for the fiscal
year ended December 31, 2019 or an auditor's report as required by paragraph (c) of Part F/S of
Form 1-A.
            We will provide more detailed comments relating to your draft offering statement
following our review of a substantive amendment that addresses these deficiencies.
            Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Frank Borger Gilligan

SecProbe.io